Melanoma Clinical Trials in Houston

Showing 201-220 of 241 trials

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

NCT00121680

The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily (qd) dosing in combination with temozolomide.

Metastatic Melanoma

Eisai Inc.115 participantsStarted Jul 2005

Dallas, Texas, United States • Houston, Texas, United States

COMPLETEDPhase 1< 1 mile

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

NCT00833807

The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.

MelanomaLiver Metastasis

M.D. Anderson Cancer Center30 participantsStarted Feb 2009

Houston, Texas, United States

COMPLETEDPhase 2< 1 mile

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664

The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks

Melanoma

Bristol-Myers Squibb158 participantsStarted Mar 2008

Los Angeles, California, United States • New Haven, Connecticut, United States • Park Ridge, Illinois, United States +29 more locations

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Phase II, 2nd Line Melanoma - RAND Monotherapy

Melanoma Trials in Other Cities

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Other Conditions in Houston